- Home
- SNT vs CTSO Comparison
SNT vs CTSO Comparison
Compare SNT & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNT
- CTSO
- Stock Information
- Founded
- SNT 1965
- CTSO 1997
- Country
- SNT Canada
- CTSO United States
- Employees
- SNT N/A
- CTSO 149
- Industry
- SNT Telecommunications Equipment
- CTSO Medical/Dental Instruments
- Sector
- SNT Telecommunications
- CTSO Health Care
- Exchange
- SNT Nasdaq
- CTSO Nasdaq
- Market Cap
- SNT 74.4M
- CTSO 68.2M
- IPO Year
- SNT 1993
- CTSO N/A
- Fundamental
- Price
- SNT $3.46
- CTSO $1.10
- Analyst Decision
- SNT
- CTSO Strong Buy
- Analyst Count
- SNT 0
- CTSO 3
- Target Price
- SNT N/A
- CTSO $4.67
- AVG Volume (30 Days)
- SNT 20.3K
- CTSO 69.1K
- Earning Date
- SNT 04-23-2025
- CTSO 05-08-2025
- Dividend Yield
- SNT N/A
- CTSO N/A
- EPS Growth
- SNT N/A
- CTSO N/A
- EPS
- SNT 0.11
- CTSO N/A
- Revenue
- SNT $35,753,000.00
- CTSO $35,594,520.00
- Revenue This Year
- SNT N/A
- CTSO $18.72
- Revenue Next Year
- SNT N/A
- CTSO $19.75
- P/E Ratio
- SNT $31.64
- CTSO N/A
- Revenue Growth
- SNT 9.03
- CTSO 14.51
- 52 Week Low
- SNT $1.27
- CTSO $0.70
- 52 Week High
- SNT $3.97
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- SNT 57.93
- CTSO 57.37
- Support Level
- SNT $2.95
- CTSO $1.05
- Resistance Level
- SNT $3.66
- CTSO $1.16
- Average True Range (ATR)
- SNT 0.19
- CTSO 0.07
- MACD
- SNT 0.05
- CTSO 0.02
- Stochastic Oscillator
- SNT 82.07
- CTSO 73.91
About SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.